Stocks To Buy Forum

Stocks to Buy based on the Best Stock Market Research

AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 in various indication ongoing =TOP PICK

Very attractive and massive undervalued Biotech Stock with many Major News on the way . Axsome has 4 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .

This undiscovered goldmine could be the next 10 bagger gem if just oneof their 4 Phase 3 program is successful .GL


Axsome (AXSM)

Market-Cap: $83 Million
Cash: $50.6 Million
Price:$3.60

Shares Out: 23 Million


Anticipated Near-Term Clinical Milestones

Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)


Clinical Trial Readouts:

-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)



New Presentation
http://redirect.viglink.com/?key=bbb516d91daee20498798694a42dd559&a...

Major Shareholders

Herriott Tabuteau, MD 7 351 729 38,4%
Fidelity Management & Research Co. 2 361 625 12,3%
JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
Mark Coleman, MD 647 998 3,38%
BlackRock Fund Advisors 426 837 2,23%
Stifel Trust Co., NA 415 279 2,17%
The Vanguard Group, Inc. 272 189 1,42%
Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
JPMorgan Investment Management, Inc. 156 625 0,82%
SSgA Funds Management, Inc. 134 688 0,70%

Views: 634

Reply to This

Stocks I'm Watching in 2017: TNA SHAK YINN UDOW SPXL SGY CLR and more...

Replies to This Discussion

maybe the cheapest Nasdaq Biotech you can get with 5x Phase 3 in various indications and a laughable Market cap of $85 Million and $50 Million in cash .The fair value should be at $8-10 right now for this unknown Biotech .

Latest stock market analyst ratings:

Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock.

Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock.

Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock.
-----

here we go guys we are over $4 ,, this stock is what i call a once in a lifetime opp this stock should be at $20 right now not at laughable $4 .

5 Phase 3 Programs two of them targeting very large Markets with NO approved Drugs .

Marketcap: $90 Million
Cash: $50 Million
Price: $3.95

New Presentation
http://phx.corporate-ir.net/Externa...9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4...

AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.

AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.

AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3


AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017.

AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.

Need to break the MA(50) at $4.24 then $5+ coming

Fantastic News out today...

Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease Agitation
https://globenewswire.com/news-release/2017/05/08/980006/0/en/Axsom...

--

Another Guy likes AXSM ...more and more people discover this stock and realize the mega potential here
https://seekingalpha.com/instablog/498952-bret-jensen/4989021-axsom...

Nice move today ,, Start Phase 2/3 of Alzheimer agitation trial within days......

Nice move today ,, Start Phase 2/3 of Alzheimer agitation trial within days......Nice move today ,, Start Phase 2/3 of Alzheimer agitation trial within days ...

Nice price jump looks like its on the way to break the size back the MA(200) at $5.54 .With positive phase 3 results in the coming weeks this low float stock will jump close or even above $10 .

Jumping today, nice stock pick!

2 BIG P3 READOUT THIS MONTH=$$$$$ GET SOME AXSM

AXSM (MC $120 M) (Cash $40 M) Shares Out 25.4 M // 7x Phase 3 programs in various indications targeting billion dollar markets ..2x Phase 3 readout expected within THIS MONTH = Could run to $20+ .Sabby Management just bought 1.4 Million shares a few days ago which is a good sign .GL

Axsome Therapeutics (AXSM)

Market Cap: $120 M
Cash $40 M
Price: $4.75

Shares Out : 25.4 M ( 16+ Million shares held alone by Management & Institutions)


Presentation from mid November (see slide 36 for upcoming milestones)
http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Pre...


Anticipated Near-Term Clinical Milestones

• Clinical Trial Readouts:

Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (late December 2017 to early January 2018)

Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (late December 2017 to early January 2018)

Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1H 2018)


Axsome Therapeutics Inc (AXSM) Stake Owned by Sabby Management, LLC...Dec 4th, 2017
https://www.themarketsdaily.com/2017/12/04/axsome-therapeutics-inc-...

Looks like the runup to phase 3 results has just begun...GL
"JPMorgan Chase & Co. increased its position in Axsome Therapeutics Inc (NASDAQ:AXSM) by 1.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,459,117 shares of the company’s stock after buying an additional 23,229 shares during the period. JPMorgan Chase & Co. owned 6.18% of Axsome Therapeutics worth $8,026,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the stock. Susquehanna International Group LLP purchased a new stake in shares of Axsome Therapeutics in the second quarter worth about $188,000. Goldman Sachs Group Inc. raised its position in Axsome Therapeutics by 118.7% during the second quarter. Goldman Sachs Group Inc. now owns 67,618 shares of the company’s stock valued at $372,000 after purchasing an additional 36,698 shares during the period. Finally, Sphera Funds Management LTD. raised its position in Axsome Therapeutics by 24.9% during the second quarter. Sphera Funds Management LTD. now owns 501,000 shares of the company’s stock valued at $2,756,000 after purchasing an additional 100,000 shares during the period. Institutional investors own 23.62% of the company’s stock."

AXSM = Market Cap $70 Million / Cash $41 Million or untill Q4 2019 / Shares Out 25.3 Million / 6x Phase 3 Programs in different indications targeting very large Markets ....Stock is a pure gift at this price


New Presentation
http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Pre...

RSS

Stocks to Buy 2018

Stocks to Buy 2018

Tesla (TSLA)
Small Cap Bull 3x (TNA)
Shake Shack (SHAK)
Stocks to Watch - 2018
Penny Stocks - 2018



Twitter - Free Stock Alerts

© 2018   Created by Stocks To Buy.   Powered by

Badges  |  Report an Issue  |  Terms of Service